Catalyst Pharmaceuticals (NASDAQ:CPRX) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1 by 4 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys. Catalyst Pharmaceuticals (NASDAQ:CPRX) stock ended Thursday session in the red zone in a volatile trading. The stock closed down 0.02 points or 1.82% at $1.08 with 610,958 shares getting traded. Post opening the session at $1.1, the shares hit an intraday low of $1.04 and an intraday high of $1.13 and the price was in this range throughout the day. The company has a market cap of $90 million and the number of outstanding shares have been calculated to be 82,880,360 shares. The 52-week high of Catalyst Pharmaceuticals (NASDAQ:CPRX) is $5.8 and the 52-week low is $0.93.
Catalyst Pharmaceuticals (NASDAQ:CPRX) should head towards $6.45 per share according to 5 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $3 per share. The higher price estimate target is at $13 according to the Analysts.
The stock has recorded a 20-day Moving Average of 5.9% and the 50-Day Moving Average is 33.05%. Investors should note that the Company has disclosed insider buying and selling activities to the Securities Exchange, Miller Steve, COO of Catalyst Pharmaceuticals, Inc., executed a transaction worth $14,279 on January 11, 2016. A total of 7,933 shares were purchased at an average price of $1.8. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. Firdapse is used for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). CPP-115 is used for the treatment of addiction and epilepsy. CPP-109 is used to treat addiction. The Company is conducting a Phase III trial to determine the safety and efficacy of Firdapse in the treatment of LEMS. CPP-115 has been granted Orphan Drug Designation by the food and drug administration (FDA) for the treatment of infantile spasms and Orphan Medicinal Product Designation in the European Union, for West syndrome (a form of infantile spasms).